LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
In April 2017, Boston Scientific Corp. filed an action against Nevro, asserting claims of patent infringement, theft of trade secrets and tortious interference with contract by recruiting and hiring dozens of former Boston Scientific Corp. employees.
Then, on July 10, 2018, various analysts reported on a tentative ruling in Nevro's ongoing patent litigation against Boston Scientific. The tentative ruling invalidated at least five of the patents related to Nevro's purportedly "proprietary" HF10 therapy and Senza systems. On this news, shares of Nevro fell $11.43 per share, or 15.15%, to close at $64.04 on July 10, 2018, thereby injuring investors.
If you purchased Nevro securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
